Kenya - English - Pharmacy and Poisons Board

ajanta pharma limited ajanta house charkop kandivli (west) mumbai 400 - carbonyl iron equivalent to elemental iron 100… - capsule - carbonyl iron equivalent to elemental iron 100… - vitamins with minerals

Kenya - English - Pharmacy and Poisons Board

zest pharma 275, sector "f", sanwer road, indore-15 india - carbonyl iron folic acid ascorbic acid… - tablet - elemental iron as carbonyl iron 100mg; folic acid… - antianemic preparations - iron preparations: iron

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boc limited - carbonyl sulfide - unknown - carbonyl sulfide mineral-sulfur active 0.0 - active constituent

India - English - Central Drugs Standard Control Organization

aristo - carbonyl iron,folic acid+elemental calcium,vit.d3 - kit - 100,1;mg(1cap)+500mg200iu.(1tab) - 10/10(cap tab)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - iron as iron carbonyl and ferric pyrophosphate; vitamin b2 = riboflavin; vitamin b1 nitrate = thiamine nitrate; cobaltous sulfate heptahydrate; glycine; lysine hydrochloride; methionine-dl; copper carbonate; vitamin b12 = cyanocobalamin; vitamin b3 = nicotinamide; vitamin b6 hydrochloride = pyridoxine hydrochloride; vitamin m = folic acid = pga - oral granules, pellets - iron as iron carbonyl and ferric pyrophosphate mineral-iron active 230.0 mg/30g; vitamin b2 = riboflavin vitamin-b2 active 25.0 mg/30g; vitamin b1 nitrate = thiamine nitrate vitamin-b1 active 15.0 mg/30g; cobaltous sulfate heptahydrate mineral-cobalt other 1.0 mg/30g; glycine amino acid-glycine other 100.0 mg/30g; lysine hydrochloride amino acid-lysine other 200.0 mg/30g; methionine-dl amino acid-methionine-dl other 100.0 mg/30g; copper carbonate mineral-copper-salt other 18.0 mg/30g; vitamin b12 = cyanocobalamin vitamin-b12 other 500.0 mg/30g; vitamin b3 = nicotinamide vitamin-b3 other 300.0 mg/30g; vitamin b6 hydrochloride = pyridoxine hydrochloride vitamin-b6 other 15.0 mg/30g; vitamin m = folic acid = pga vitamin-m other 7.5 mg/30g - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - iron deficiency | mineral and nutritional additive | acetonaemia | actinobacillosis | amino acid supplement | amino acids | anaemia | bone fragility | bone growth | calcium supplement | cartilage strength | copper deficiency | egg shell | fatty acid deficiency | fatty liver | glucose | grass tetany | hepatotoxic drugs | hypocalcaemia | hypomagnesaemia | ileitis | iodine deficiencies | lactating | laxative | l-carnitine supplement | liver abscess | liver damage | lysine deficiencies | milk fever | mineral additive | myopathies | myositis syndrome | pangamic acid | phosphorous supplement | rickets | selenium deficiency | shell strength | soft bone disease | vitamin b12 | vitamin d supplement | vitamin e deficiencies | zinc deficiencies

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. heart failure enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decreases the incidence of hospitalization for hea

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, usp, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, usp, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings , head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - hypertension quinapril tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation,

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and